# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Yi Chen reiterates CareDx (NASDAQ:CDNA) with a Neutral.
Raymond James analyst Andrew Cooper downgrades CareDx (NASDAQ:CDNA) from Outperform to Market Perform.
Goldman Sachs analyst Matthew Sykes maintains CareDx (NASDAQ:CDNA) with a Buy and raises the price target from $10 to $14.
Stephens & Co. analyst Mason Carrico maintains CareDx (NASDAQ:CDNA) with a Overweight and raises the price target from $...
CareDx (NASDAQ:CDNA) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.21) by 85....